1. Market Research
  2. > Microalbuminuria - Pipeline Review, H1 2013

Microalbuminuria - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 26 pages

Microalbuminuria - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Microalbuminuria - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Microalbuminuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Microalbuminuria. Microalbuminuria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Microalbuminuria.
- A review of the Microalbuminuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Microalbuminuria pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Microalbuminuria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Microalbuminuria pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Microalbuminuria - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Microalbuminuria Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Microalbuminuria 6
Microalbuminuria Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Microalbuminuria Therapeutics - Products under Development by Companies 11
Companies Involved in Microalbuminuria Therapeutics Development 12
Bristol-Myers Squibb Company 12
FibroGen, Inc. 13
Microalbuminuria - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
FG-3019 - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
BMS-813160 - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Microalbuminuria Therapeutics - Drug Profile Updates 22
Microalbuminuria Therapeutics - Discontinued Products 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26

List of Tables


Number of Products Under Development for Microalbuminuria, H1 2013 6
Products under Development for Microalbuminuria - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Mid Clinical Stage Development, H1 2013 9
Comparative Analysis by Early Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Bristol-Myers Squibb Company, H1 2013 12
FibroGen, Inc., H1 2013 13
Assessment by Monotherapy Products, H1 2013 14
Assessment by Stage and Route of Administration, H1 2013 16
Assessment by Stage and Molecule Type, H1 2013 18
Microalbuminuria Therapeutics - Drug Profile Updates 22
Microalbuminuria Therapeutics - Discontinued Products 24

List of Figures


Number of Products under Development for Microalbuminuria, H1 2013 6
Products under Development for Microalbuminuria - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Mid Clinical Stage Products, H1 2013 9
Early Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 14
Assessment by Route of Administration, H1 2013 15
Assessment by Stage and Route of Administration, H1 2013 16
Assessment by Molecule Type, H1 2013 17
Assessment by Stage and Molecule Type, H1 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.